Forecasting & Franchise Strategy
Strengthen your portfolio by making more informed decisions and prepare for the impact of new research discoveries.
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell & Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases & Vaccines
- Oncology & Hematology
- Pediatrics
- Rare Diseases
- View All
The IQVIA difference
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
Innovation at IQVIA
Extraordinary outcomes are built on curiosity, creativity, and the relentless pursuit of smarter healthcare for all. Our breakthroughs power our solutions, supporting the needs of our partners – and their patients.
Explore our innovationsIQVIA Patient Experience Solutions powered by Apple
Global Trends in R&D 2025. By collaborating with Apple, IQVIA is able to use devices that patients already have and know how to use to empower them to personalize their healthcare & connecting them to caregivers.
visit IQVIA Patient Experience Solutions
IQVIA Patient Experience Solutions powered by Apple
"IQVIA thought leadership with a focus on EMEA.
visit IQVIA Patient Experience Solutions
IQVIA Patient Experience Solutions powered by Apple
"By collaborating with Apple, IQVIA is able to use devices that patients already have and know how to use to empower them to personalize their healthcare & connecting them to caregivers.
visit IQVIA Patient Experience Solutions
IQVIA Patient Experience Solutions powered by Apple
"By collaborating with Apple, IQVIA is able to use devices that patients already have and know how to use to empower them to personalize their healthcare & connecting them to caregivers.
visit IQVIA Patient Experience SolutionsBLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSFEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI®
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Global Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREMeet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREIQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREIQVIA Careers
Featured Careers
Stay Connected
WE'RE HIRING
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESWhite Paper
KRAS Mutation: An Update on Key Selected Pipeline Developments and Clinical Trials for KRAS Targeting Therapies
IQVIA Pipeline Link / IQVIA Trial Link
Jun 20, 2024
Some of the deadliest cancers harbor mutations in the Kirsten Rat Sarcoma virus (KRAS) gene. The recent development of therapies that target and kill cancer cells with these mutations was heralded as a significant breakthrough. First identified in 1982, KRAS mutations are involved in approximately 25% of human cancers. The US FDA's approval of Amgen's sotorasib (LUMAKRAS) in May 2021 marks the first time that marketing authorization has been granted to a KRAS targeted therapy.
This article provides an update on current treatment options for KRAS-driven tumors and outlines the latest development activities including ongoing clinical trials of key experimental drugs with data sourced from IQVIA Pipeline Link and the newly launched IQVIA Trial Link.
Mode of action
The KRAS gene is an oncogene that encodes the KRAS protein, a GTPase transductor protein, which is part of the RAS/MAPK signaling pathway and provides instructions to cells to proliferate. The KRAS protein converts the GTP molecule into the GDP molecule and acts as a switch that is turned on and off by these molecules. The KRAS protein is activated by binding to a GTP molecule and inactivated when it converts GTP to GDP as it does not relay signals to the cells when the protein is bound to GDP. Oncogenes have the potential to cause normal cells to become cancerous when mutated. The KRAS gene is a member of the RAS family of oncogenes, which also includes the Harvey Rat Sarcoma virus (HRAS) and Neuroblastoma Rat Sarcoma virus (NRAS) genes. These proteins play important roles in cell division, cell differentiation and apoptosis of cells. The activation of KRAS mutation occurs when there is a shift in balance of the KRAS protein to a GTP-loaded active state, which triggers tumor proliferation.
Discover more by downloading the article. It covers treatment options, next-generation drugs for KRAS-mutant tumors, clinical trial analysis, and highlights early-stage KRAS inhibitors.